Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
Status:
Recruiting
Trial end date:
2027-06-10
Target enrollment:
Participant gender:
Summary
This is a randomized clinical trial that randomizes between treatment principles. The study
will investigate if precision therapy determined by a tumour board is better than standard
treatment for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in elderly.
The tumour board will decide the precision therapy based on identified genetic changes that
can guide customized therapy. There are currently 40-50 targeted therapies approved for
various cancers in Norway. The precision therapy will be given in addition to the standard
treatment.
The primary study objective will be to evaluate the cost-effectiveness of a precision therapy
strategy compared with standard treatment. Other objectives will mesaure efficacy and satety
of the treatment, and impact on life quality of the patients.